1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Celladon Corporation - Product Pipeline Review - 2014

Celladon Corporation - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 27 pages

Celladon Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Celladon Corporation - Product Pipeline Review - 2014’, provides an overview of the Celladon Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celladon Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Celladon Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Celladon Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Celladon Corporation’s pipeline products

Reasons to buy

- Evaluate Celladon Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Celladon Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Celladon Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Celladon Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celladon Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Celladon Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Celladon Corporation - Product Pipeline Review - 2014
Table of Contents
Celladon Corporation Snapshot 4
Celladon Corporation Overview 4
Key Information 4
Key Facts 4
Celladon Corporation- Research and Development Overview 5
Key Therapeutic Areas 5
Celladon Corporation- Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products- Monotherapy 8
Celladon Corporation- Pipeline Products Glance 9
Celladon Corporation- Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Celladon Corporation- Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Celladon Corporation- Drug Profiles 11
Mydicar 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Gene therapy to Activate mSCF for Ischemic Cardiomyopathy 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Small Molecule Modulators of SERCA2b for Metabolic and Neurodegenerative Disorders 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Celladon Corporation- Pipeline Analysis 16
Celladon Corporation- Pipeline Products by Target 16
Celladon Corporation- Pipeline Products by Route of Administration 17
Celladon Corporation- Pipeline Products by Molecule Type 18
Celladon Corporation- Pipeline Products by Mechanism of Action 19
Celladon Corporation- Recent Pipeline Updates 20
Celladon Corporation- Dormant Projects 24
Celladon Corporation- Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables

Celladon Corporation, Key Information 4
Celladon Corporation, Key Facts 4
Celladon Corporation- Pipeline by Indication, 2014 6
Celladon Corporation- Pipeline by Stage of Development, 2014 7
Celladon Corporation- Monotherapy Products in Pipeline, 2014 8
Celladon Corporation- Phase II, 2014 9
Celladon Corporation- Preclinical, 2014 10
Celladon Corporation- Pipeline by Target, 2014 16
Celladon Corporation- Pipeline by Route of Administration, 2014 17
Celladon Corporation- Pipeline by Molecule Type, 2014 18
Celladon Corporation- Pipeline Products by Mechanism of Action, 2014 19
Celladon Corporation- Recent Pipeline Updates, 2014 20
Celladon Corporation- Dormant Developmental Projects,2014 24

List of Figures

Celladon Corporation - Pipeline by Top 10 Indication, 2014 6
Celladon Corporation - Pipeline by Stage of Development, 2014 7
Celladon Corporation - Monotherapy Products in Pipeline, 2014 8
Celladon Corporation - Pipeline by Top 10 Target, 2014 16
Celladon Corporation - Pipeline by Top 10 Route of Administration, 2014 17
Celladon Corporation - Pipeline by Top 10 Molecule Type, 2014 18
Celladon Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) ...

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NADPH ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.